Table 3.
Recommended clinical endpoints for trials in patients with malignant melanoma, non-small cell lung cancer, or renal cell carcinoma.
| Malignant melanoma [17] |
NSCLC [18, 19] |
RCC [20, 21] |
|---|---|---|
| Overall survivala | Disease stability | Median overall survival |
|
| ||
| Progression-free survival | Growth modulation index | Median progression-free survival |
|
| ||
| Quality of life | Median overall survival | Response rate |
|
| ||
| Median progression-free survival | ||
|
| ||
| Time to progression | ||
aThe article did not specify median or mean OS.